Merck Launches Campaign to Support UK Carers
Merck, Darmstadt, Germany has announced that its Embracing Carers™ initiative has launched a new campaign to help individuals in the UK reflect and recognize their unpaid caring role sooner and access available support and resources faster. Developed by Merck, Darmstadt, Germany and guided by Carers UK and other leading international carer organizations, Embracing Carers™ is a global movement to highlight the important role of carers in society. With up to 6,000 people a day in the UK becoming carers, Embracing Carers has launched the “By Day, By Night initiative”. The campaign aims to help individuals reflect on their daily lives and help those in the UK recognize their role as a carer. 6.5 million people (around 10 per cent of the UK population) are carers and the majority take a long time to recognize their caring role. Research by Carers UK shows that over half (54%) of carers in the country took over a year to recognize their caring role and nearly a quarter (24%) took over five years to recognize their role as a carer.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
